By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


Key Statistics

Ownership: Public

Web Site: Adamas Pharma
Symbol: ADMS



Company News
Adamas Pharma (ADMS) Presents Positive Phase Ia Data Of ADS-4101 (Lacosamide) For The Treatment Of Partial Onset Seizures In Epilepsy 5/22/2017 8:22:21 AM
Adamas Pharma (ADMS) Signs $100 Million Royalty-Backed Note Agreement With Healthcare Royalty Partners 5/11/2017 8:42:48 AM
Adamas Pharma (ADMS) Reports Inducement Grant To New Chief Operating Officer 5/8/2017 10:46:27 AM
Adamas Pharma (ADMS) To Announce First Quarter 2017 Financial Results And Host Conference Call On May 9, 2017 5/3/2017 7:31:20 AM
Adamas Pharma (ADMS) Appoints Richard A. King4/28/2017 10:35:28 AM
Adamas Pharma (ADMS) Presents ADS-5102 Pooled Phase III Data Confirming Statistically Significant Reduction In Levodopa-Induced Dyskinesia And OFF Time In People With Parkinson’s Disease 4/24/2017 9:16:30 AM
Adamas Pharma (ADMS) Announces New Employment Inducement Grant 3/13/2017 8:21:43 AM
Adamas Pharma (ADMS) Reports Recent Achievements And Financial Results For The Fourth Quarter And Full-Year 2016 3/1/2017 12:12:21 PM
Adamas Pharma (ADMS) Presents Additional Open-Label, Long-Term Safety And Efficacy Data On ADS-5102 At The First Pan American Parkinson’s Disease And Movement Disorders Congress 2/28/2017 8:10:43 AM
Adamas Pharma (ADMS) To Present New ADS-5102 Data From Phase II Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017 2/17/2017 8:56:09 AM